Unknown

Dataset Information

0

DNA damaging agents in ovarian cancer.

ABSTRACT: Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging role of PARP inhibitors has changed the landscape of opportunities for patients with EOC. All these strategies will be reviewed in this article.

SUBMITTER: Barretina-Ginesta MP 

PROVIDER: S-EPMC7573464 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

DNA damaging agents in ovarian cancer.

Barretina-Ginesta Maria-Pilar MP  

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] 20200822

Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging ro  ...[more]

Similar Datasets

Unknown Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.
| S-EPMC5432342 | biostudies-literature
Unknown MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.
| S-EPMC5837749 | biostudies-literature
Transcriptomics Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA
2020-08-21 | GSE156543 | GEO
Clinical Chemotherapy With DNA Damaging Agents In Colorectal Cancer
| 2114543 | ecrin-mdr-crc
Unknown Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
| S-EPMC3443151 | biostudies-literature
Unknown Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
| S-EPMC4573818 | biostudies-literature
Unknown CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents.
| S-EPMC5710876 | biostudies-literature
Unknown Polymerase ? suppresses telomere defects induced by DNA damaging agents.
| S-EPMC4245935 | biostudies-literature
Transcriptomics Identifying Novel Predictors of Resistance to DNA Damaging Agents
2008-09-23 | GSE10313 | GEO
Unknown USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.
| S-EPMC6825982 | biostudies-literature